retatrutide fat loss clinical trial results New Phase 3 data just dropped 👀 Eli Lilly's reported average weight approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Retatrutide Results: 24% Weight Loss

One must have a BMI of 30 or above, or a BMI of at least 27 or above with a weight-related health condition like high blood pressure, diabetes, or high cholesterol

Affiliate participation does not affect placement, ranking, or editorial coverage on this page

Absolute contraindication for anyone with personal or family history of medullary thyroid cancer or MEN2 syndrome

Clinical Trial Status: Where Each Compound Stands in 2026 Tirzepatide (Fully Approved) Tirzepatide completed its regulatory journey and received: FDA approval as Mounjaro (2022) for type 2 diabetes management FDA approval as Zepbound (2023) for chronic weight management in adults with obesity or overweight with weight-related comorbidities It is available via prescription from licensed healthcare providers in the United States and many other countries

I find the amylin story more interesting than most of the GLP-1 hype, because it targets the part of appetite that wrecks diets at night, the mindless grazing

Comparing percentages from separate trials can be misleading because trial populations and methods differ